Prognostic Significance of Flow Cytometric Immunophenotyping in Patients with Acute Myeloid Leukemia

Objective:Chromosomal abnormalities are one of the most important prognostic factors in acute myeloid leukemia (AML). However, not all patients may have such informative chromosomal abnormalities. Although there are many studies on the prognostic value of immunophenotyping in AML, it is still not us...

Full description

Bibliographic Details
Main Authors: Sinan DEMİRCİOĞLU, Ömer EKİNCİ, Ali DOĞAN, Turgay ULAŞ
Format: Article
Language:English
Published: Galenos Publishing House 2022-08-01
Series:Bezmiâlem Science
Subjects:
Online Access: http://bezmialemscience.org/archives/archive-detail/article-preview/prognostic-significance-of-flow-cytometric-mmunoph/52680
_version_ 1797916839209074688
author Sinan DEMİRCİOĞLU
Ömer EKİNCİ
Ali DOĞAN
Turgay ULAŞ
author_facet Sinan DEMİRCİOĞLU
Ömer EKİNCİ
Ali DOĞAN
Turgay ULAŞ
author_sort Sinan DEMİRCİOĞLU
collection DOAJ
description Objective:Chromosomal abnormalities are one of the most important prognostic factors in acute myeloid leukemia (AML). However, not all patients may have such informative chromosomal abnormalities. Although there are many studies on the prognostic value of immunophenotyping in AML, it is still not used as a prognostic marker. In this study, we aimed to investigate the effects of CD13, CD33, CD34, CD117, MPO and HLADR expressions on prognosis of non-acute promyelocytic leukemia AML.Methods:One hundred thirteen patients diagnosed as having non- acute promyelocytic leukemia AML and followed up between 2010 and 2018 were included in this study. The associations of CD13, CD33, CD34, CD117, MPO and HLA DR expressions with chemotherapy response, progression free survival (PFS) and overall survival (OS) were statistically analyzed.Results:It was seen that response to chemotherapy was achieved in 67.3% of the patients. Median PFS duration was 9 months and median OS duration was found as 13 months. Of the immunophenotypic characteristics, only MPO expression was determined to be an independent risk factor for PFS and OS.Conclusion:Immunophenotypic features may be helpful in the diagnosis of AML as well as give an idea about prognosis. In this study, MPO expression was shown to be an independent risk factor for PFS and OS in our own patient population.
first_indexed 2024-04-10T13:03:43Z
format Article
id doaj.art-6216e4967c524ad7bc6db8917f8320da
institution Directory Open Access Journal
issn 2148-2373
language English
last_indexed 2024-04-10T13:03:43Z
publishDate 2022-08-01
publisher Galenos Publishing House
record_format Article
series Bezmiâlem Science
spelling doaj.art-6216e4967c524ad7bc6db8917f8320da2023-02-15T16:13:03ZengGalenos Publishing HouseBezmiâlem Science2148-23732022-08-0110440240810.14235/bas.galenos.2021.587513049054Prognostic Significance of Flow Cytometric Immunophenotyping in Patients with Acute Myeloid LeukemiaSinan DEMİRCİOĞLU0Ömer EKİNCİ1Ali DOĞAN2Turgay ULAŞ3 Necmettin Erbakan University Meram Faculty of Medicine, Department of Hematology, Konya, Turkey Fırat University Faculty of Medicine, Department of Hematology, Elazığ, Turkey Van Yüzüncü Yıl University Faculty of Medicine, Department of Hematology, Van, Turkey Yakın Doğu University Faculty of Medicine, Department of Hematology, Lefkoşa, Northern Cyprus TR Objective:Chromosomal abnormalities are one of the most important prognostic factors in acute myeloid leukemia (AML). However, not all patients may have such informative chromosomal abnormalities. Although there are many studies on the prognostic value of immunophenotyping in AML, it is still not used as a prognostic marker. In this study, we aimed to investigate the effects of CD13, CD33, CD34, CD117, MPO and HLADR expressions on prognosis of non-acute promyelocytic leukemia AML.Methods:One hundred thirteen patients diagnosed as having non- acute promyelocytic leukemia AML and followed up between 2010 and 2018 were included in this study. The associations of CD13, CD33, CD34, CD117, MPO and HLA DR expressions with chemotherapy response, progression free survival (PFS) and overall survival (OS) were statistically analyzed.Results:It was seen that response to chemotherapy was achieved in 67.3% of the patients. Median PFS duration was 9 months and median OS duration was found as 13 months. Of the immunophenotypic characteristics, only MPO expression was determined to be an independent risk factor for PFS and OS.Conclusion:Immunophenotypic features may be helpful in the diagnosis of AML as well as give an idea about prognosis. In this study, MPO expression was shown to be an independent risk factor for PFS and OS in our own patient population. http://bezmialemscience.org/archives/archive-detail/article-preview/prognostic-significance-of-flow-cytometric-mmunoph/52680 acute myeloid leukemiaimmunophenotypingprognosissurvival
spellingShingle Sinan DEMİRCİOĞLU
Ömer EKİNCİ
Ali DOĞAN
Turgay ULAŞ
Prognostic Significance of Flow Cytometric Immunophenotyping in Patients with Acute Myeloid Leukemia
Bezmiâlem Science
acute myeloid leukemia
immunophenotyping
prognosis
survival
title Prognostic Significance of Flow Cytometric Immunophenotyping in Patients with Acute Myeloid Leukemia
title_full Prognostic Significance of Flow Cytometric Immunophenotyping in Patients with Acute Myeloid Leukemia
title_fullStr Prognostic Significance of Flow Cytometric Immunophenotyping in Patients with Acute Myeloid Leukemia
title_full_unstemmed Prognostic Significance of Flow Cytometric Immunophenotyping in Patients with Acute Myeloid Leukemia
title_short Prognostic Significance of Flow Cytometric Immunophenotyping in Patients with Acute Myeloid Leukemia
title_sort prognostic significance of flow cytometric immunophenotyping in patients with acute myeloid leukemia
topic acute myeloid leukemia
immunophenotyping
prognosis
survival
url http://bezmialemscience.org/archives/archive-detail/article-preview/prognostic-significance-of-flow-cytometric-mmunoph/52680
work_keys_str_mv AT sinandemircioglu prognosticsignificanceofflowcytometricimmunophenotypinginpatientswithacutemyeloidleukemia
AT omerekinci prognosticsignificanceofflowcytometricimmunophenotypinginpatientswithacutemyeloidleukemia
AT alidogan prognosticsignificanceofflowcytometricimmunophenotypinginpatientswithacutemyeloidleukemia
AT turgayulas prognosticsignificanceofflowcytometricimmunophenotypinginpatientswithacutemyeloidleukemia